



Baseline demographics, laboratory results, physical measurements and EQ-5D scores were all 
considered as predictors of mortality during the first 48 weeks on ART, after which participants 
exited the trial (Table 1, Supplementary Table 1). Illnesses and symptoms reported at enrolment 
were included if they occurred in >5% of participants; highly-related symptoms were identified 
through hierarchical clustering of all symptoms across patients and pallor (grouped with difficulty 
walking) and weakness, poor appetite and cough (grouped with weight loss) excluded. The mean of 
continuous factors measured at both screening and enrolment visits was used. Continuous factors 
that were highly correlated (Spearman rho>0.9) or missing in >10% were also excluded (namely body 
fat %, muscle mass, total body water, total body water %, bone mass, basal metabolic rate, CD3, 
CD8, lymphocytes, lymphocytes %, neutrophils %, MCV, red blood cells, haematocrit, phosphate, 
bilirubin, ALT and AST). Continuous factors with evidence of outliers were truncated at the 1st, 5th, 
95th or 99th percentile based on the distribution. Previous healthcare contact was defined as having a 
chronic health condition (e.g. diabetes, hypertension) or having medication prescribed at least 14 
days prior to the screening visit. 
 
Factors were selected for the final Cox proportional hazards model using backwards elimination (exit 
p>0.1 to build an explanatory model, reporting only factors with p<0.05). Non-linearity was included 
in the model building process using multivariable fractional polynomials if p<0.05 (stata mfp). Clinical 
centre (reflecting clinical management and access to diagnostic facilities) was included in all models. 
Models were restricted to complete cases, so after initial variable selection a final model was 
refitted to all observations with complete data and the remaining factors were re-checked and 
included if p<0.1. All continuous factors were included in final models with linear effects, ie each unit 
increase had the same impact on mortality at all levels of the factor. The only interaction (p<0.01) 
between factors in this model was between albumin and fever (p=0.002). This suggested that 
albumin had little effect on mortality in the 13% of patients reporting fever at baseline (HR=1.00 per 
g/l higher (95% CI 0.97-1.04)) compared with higher albumin significantly reducing risk in the 87% 
without fever at baseline (HR=0.94 (0.91-0.96)). As the effects of other factors were similar including 
or excluding this interaction, it was not included in final models.  
 
Different patterns of “late presenters” were identified using cluster analysis. First, principal 
components analysis of the correlation matrix was used to reduce the continuous factors to the 
smallest number of components that explained >75% of the variance. Hierarchical clustering then 
used Ward’s linkage on these principal components and remaining binary factors with the number of 
clusters determined using the Duda-Hart stopping rule. 
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Supplementary Table 1 Other baseline factors not considered as predictors of mortality due to 
incompleteness, collinearity with other factors already being considered, or reflecting subsequent 
treatment 
 Died before 48 
weeks 
N=255 




Temperature (˚C) (N=1793) 36.7 (36.2, 37.3) 36.5 (36.2, 36.9) 36.5 (36.2, 36.9) 
Height (cm) (N=1798) 163 (157, 169) 164 (158, 171) 164 (158, 171) 
Weight (kg) (N=1800) 49.3 (42.1, 53.9) 53.2, (46.8, 59.9) 52.5 (46.3, 59.3) 
CD3 (cells/mm3) (N=1734) 431 (295, 691) 584 (386, 843) 564 (368, 828) 
CD4% (N=1351) 5 (3, 8) 5 (3, 8) 5 (3, 8) 
CD8 (cells/mm3)  (N=1693)  394 (241, 615) 501 (319, 748) 482 (308, 726) 
CD8% (N=1350) 82 (62, 90) 70 (56, 86) 71 (57, 87) 
CD4/CD8 ratio (N=1693) 0.06 (0.03, 0.11) 0.07 (0.04, 0.12) 0.07 (0.04, 0.12) 
Red blood cells (1012/l) (N=952) 3.79 (3.18, 4.43) 4.29 (3.71, 4.75) 4.20 (3.64, 4.71) 
Haemoglobin (g/dl) (N=1802) 10.0 (8.4, 11.6) 11.4 (9.7, 12.8) 11.2 (9.6, 12.7) 
   Grade 1 or 2 74 (33%) 359 (23%) 433 (24%) 
   Grade 3 or 4 37 (16%) 80 (5%) 117 (6%) 
White blood cells (109/l) (N=1802) 3.9 (2.9, 5.4) 3.5 (2.7, 4.6) 3.5 (2.7, 4.7) 
   Grade 1 or 2 39 (17%) 303 (19%) 342 (19%) 
   Grade 3 or 4 3 (1%) 31 (2%) 34 (2%) 
Platelets (109/l) (N=1801) 260 (189, 341) 251 (182, 343) 252 (183, 343) 
   Grade 1 or 2 22 (10%) 128 (8%) 150 (8%) 
   Grade 3 or 4 1 (<1%) 23 (1%) 24 (1%) 
Neutrophils (109/l) (N=1785) 1.99 (1.38, 3.07) 1.69 (1.15, 2.50) 1.72 (1.17, 2.58) 
   Grade 1 or 2 23 (10%) 244 (15%) 267 (15%) 
   Grade 3 or 4 8 (4%) 33 (2%) 41 (2%) 
Lymphocytes (109/l)  (N=1792) 0.86 (0.58, 1.20) 0.98 (0.69, 1.39) 0.96 (0.68, 1.35) 
   Grade 1 or 2 37 (17%) 189 (12%) 226 (13%) 
   Grade 3 or 4 36 (16%) 143 (9%) 179 (10%) 
Lymphocytes % (N=1748) 22.1 (14.2, 32.0) 29.1 (21.2, 38.0) 28.4 (20.0, 37.4) 
Neutrophils % (N=1739) 53.0 (41.7, 68.1) 50.0 (39.3, 61.3) 50.3 (39.6, 61.8) 
Haematocrit (%) (N=695) 30.0 (25.4, 35.3) 34.5 (29.2, 38.8) 33.9 (28.7, 38.4) 
MCV (fl) (N=1694) 83 (77, 88) 84 (79, 89) 84 (79, 89) 
AST (U/I) (N=791) 49 (33, 74) 38 (28, 57) 39 (29, 61) 
   Grade 1 or 2 52 (23%) 199 (13%) 251 (14%) 
   Grade 3 or 4 4 (2%) 6 (<1%) 10 (1%) 
Creatinine (umol/l) (N=1796) 76 (60, 97) 71 (57, 86) 71 (57, 87) 
ALT (U/I) (N=1772) 27 (16, 41) 26 (17, 42) 26 (17, 41) 
   Grade 1 or 2 35 (15%) 270 (17%) 305 (17%) 
   Grade 3 or 4 2 (1%) 5 (<1%) 7 (<1%) 
Bilirubin (umol/l) (N=1767) 6 (4, 10) 6 (4, 9) 6 (4, 9) 
   Grade 1 or 2 9 (4%) 27 (2%) 36 (2%) 
   Grade 3 or 4 2 (1%) 5 (<1%) 7 (<1%) 
Phosphate (mg/dl) (N=1445) * 2.06 (1.14, 3.58) 1.45 (1.08, 3.20) 1.49 (1.09, 3.26) 
Malaria test done 6 (3%) 13 (1%) 19 (1%) 
Ultrasound performed 3 (1%) 7 (0.4%) 10 (1%) 
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X ray performed 6 (3%) 10 (1%) 16 (1%) 
AFB performed 3 (1%) 7 (<1%) 10 (1%) 
Any investigation performed 15 (7%) 34 (2%) 49 (3%) 
Physician-reported conditions    
Herpes simplex*    
   Current 1 (<1%) 9 (1%) 10 (1%) 
   Previous 1 (<1%) 7 (<1%) 8 (<1%) 
Septicaemia*    
   Current 0 1 (<1%) 1 (<1%) 
   Previous 1 (<1%) 4 (<1%) 5 (<1%) 
Anaemia    
   Current 6 (3%) 13 (1%) 19 (1%) 
   Previous 1 (<1%) 11 (1%) 12 (1%) 
Chronic diarrhoea*    
   Current 3 (1%) 45 (3%) 48 (3%) 
   Previous 11 (5%) 75 (5%) 86 (5%) 
Kaposi’s sarcoma    
   Current 3 (1%) 11 (1%) 14 (1%) 
Abscess *    
   Current 1 (<1%) 2 (<1%) 3 (<1%) 
   Previous 1 (<1%) 5 (<1%) 6 (<1%) 
Meningitis*    
   Current 3 (1%) 1 (<1%) 4 (<1%) 
   Previous 1 (<1%) 3 (<1%) 4 (<1%) 
Pneumonia*    
   Current 10 (4%) 26 (2%) 36 (2%) 
   Previous 11 (5%) 62 (4%) 73 (4%) 
Cryptococcus*    
   Current 4 (2%) 17 (1%) 21 (1%) 
   Previous 2 (1%) 1 (<1%) 3 (<1%) 
Chronic fever*    
   Current 10 (4%) 14 (1%) 24 (1%) 
   Previous 7 (3%) 9 (<1%) 16 (<1%) 
Other infection*    
   Current 1 (<1%) 5 (<1%) 6 (<1%) 
   Previous 1 (<1%) 8 (1%) 9 (1%) 
Any infection (* above, or TB or 
WHO 3/4  candida) 
   
   Current 79 (35%) 382 (24%) 461 (26%) 
   Previous 34 (15%) 234 (15%) 268 (15%) 
Previous wasting/severe weight loss 
(WHO 3/4) 
19 (8%) 63 (4%) 82 (5%) 
Previous TB (all) (WHO 3/4) 6 (3%) 37 (2%) 43 (2%) 
Previous candida (WHO 3/4) 25 (11%) 133 (8%) 158 (9%) 
Patient reported symptoms    
Dehydration  36 (16%) 59 (4%) 95 (5%) 
Ear discharge  8 (4%) 22 (1%) 30 (2%) 
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Jaundice 5 (2%) 16 (1%) 21 (1%) 
Visual problems 17 (8%) 48 (3%) 65 (4%) 
Bruises 8 (4%) 28 (2%) 36 (2%) 
Poor sleep 32 (14%) 105 (7%) 137 (8%) 
Muscle ache 37 (16%) 124 (8%) 161 (9%) 
Headache 15 (7%) 49 (3%) 64 (4%) 
Difficulty breathing 21 (9%) 39 (2%) 60 (3%) 
Diarrhoea 21 (9%) 93 (6%) 114 (6%) 
Weakness 151 (67%) 526 (33%) 677 (38%) 
Pallor 71 (32%) 154 (10%) 225 (12%) 
Poor appetite/difficulty feeding 122 (54%) 458 (29%) 580 (32%) 
Cough 82 (36%) 275 (17%) 357 (20%) 
Depression  35 (16%) 120 (8%) 155 (9%) 
Body fat % (N=1743) 9.8 (4.6, 19.0) 13.1 (8.0, 22.8) 12.8 (7.7, 22.6) 
Lean (muscle) mass (kg) (N=1740) 38.8 (35.3, 44.7) 41.6 (37.4, 47.2) 41.3 (37.0, 46.8) 
Total body water (kg) (N=1731) 29.8 (25.9, 34.4) 31.6 (27.4, 35.4) 31.3 (27.3, 35.3) 
Total body water % (N=1731) 63.6 (56.4, 70.1) 60.3 (53.3, 65.6) 60.7 (53.5, 65.9) 
Bone mass (kg) (N=1675) 2.1 (1.9, 2.4) 2.3 (2.0, 2.5) 2.3 (2.0, 2.5) 
Basal metabolic rate (kcal) (N=1674) 1218 (1128, 1371) 1312 (1201, 1450) 1303 (1192, 1441) 
Treatment    
Started ART with efavirenz 203 (90%) 1416 (90%) 1619 (90%) 
Started ART with tenofovir/ 
emtricitabine 
170 (76%) 1252 (79%) 1422 (79%) 
Initial ART regimen (excluding 
raltegravir) 
   
 Tenofovir/emtricitabine/efavirenz 164 (73%) 1214 (77%) 1378 (76%) 
 Zidovudine/lamivudine/efavirenz 29 (13%) 150 (10%) 179 (10%) 
 Zidovudine/lamivudine/nevirapine 15 (7%) 129 (8%) 144 (8%) 
 Abacavir/lamivudine/efavirenz 10 (4%) 45 (3%) 55 (3%) 
 Tenofovir/emtricitabine/nevirapine 6 (3%) 32 (2%) 38 (2%) 
 Other 1 (<1%) 10 (1%) 11 (1%) 
Receiving isoniazid pre-
randomization  
29 (13%) 148 (9%) 177 (10%) 
Receiving isoniazid at randomization    
   Treatment 31 (14%) 191 (12%) 222 (12%) 
   Prophylaxis 83 (37%) 704 (45%) 787 (44%) 
Receiving fluconazole pre-
randomization 
40 (18%) 165 (10%) 205 (11%) 
Receiving fluconazole at 
randomization 
   
   Treatment 31 (14%) 117 (7%) 148 (8%) 
   Prophylaxis 89 (40%) 772 (49%) 861 (48%) 
Receiving azithromycin at 
randomization 
   
   Treatment 2 (1%) 11 (1%) 13 (1%) 
   Prophylaxis 98 (44%) 805 (51%) 903 (50%) 
Receiving albendazole at    
5 
 Died before 48 
weeks 
N=255 





   Treatment 0  4 (0.3%) 4 (0.2%) 
   Prophylaxis 98 (44%) 806 (51%) 904 (50%) 
Receiving cotrimoxazole/dapsone at 
randomization 
   
   Cotrimoxazole: prophylaxis 221 (98%) 1545 (98%) 1766 (98%) 
   Cotrimoxazole: treatment 1 (0.4%) 3 (0.2%) 4 (0.2%) 
   Dapsone: prophylaxis 3 (1%) 29 (2%) 32 (2%) 
Receiving other antibiotics at 
randomization 
44 (19%) 154 (10%) 198 (11%) 
Number of non-ART drugs receiving 
at randomization  
3 (2,4) 3 (2,4) 3 (2,4) 
   1  30 (13%) 266 (17%) 296 (16%) 
   2 52 (22%) 330 (21%) 378 (21%) 
   3 41 (19%) 353 (23%) 401 (22%) 
   4 58 (26%) 360 (23%) 418 (23%) 
   5 19 (8%) 145 (9%) 164 (9%) 
   6 9 (4%) 70 (4%) 79 (4%) 
   7+ 16 (7%) 46 (3%) 62 (3%) 
* counted as any infection.
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Supplementary Table 2 Characteristics of different groups of late presenters 
 Group 1 Group 2 Group 3 Group 4 Group 5 Total 
 N=355 N=394 N=242 N=218 N=398 1607 
Died 87 (25%) 45 (11%) 25 (10%) 12 (6%) 15 (4%) 184 (11%) 
Died by 12 weeks 65 (18%) 28 (7%) 12 (5%) 7 (3%) 5 (1%) 117 (7%) 
Male 194 (55%) 255 (65%) 58 (24%) 6 (3%) 343 (86%) 856 (53%) 
Age (years) 36 (29, 41) 35 (30, 42) 30 (23, 38) 36 (29, 41) 39 (33, 45) 36 (29, 42) 
Ever smoked 79 (22%) 99 (25%) 11 (5%) 4 (2%) 112 (28%) 305 (19%) 
WHO stage       
      1 51 (14%) 53 (13%) 30 (12%) 32 (15%) 83 (21%) 249 (15%) 
      2 47 (13%) 89 (23%) 82 (34%) 117 (54%) 165 (41%) 500 (31%) 
      3 154 (43%) 199 (51%) 104 (43%) 54 (25%) 123 (31%) 634 (39%) 
      4 103 (29%) 53 (13%) 26 (11%) 15 (7%) 27 (7%) 224 (14%) 
Hospitalized at randomization 12 (3%) 2 (1%) 0 (0%) 0 (0%) 0 (0%) 14 (1%) 
Previous healthcare contact 49 (14%) 27 (7%) 21 (9%) 8 (4%) 33 (8%) 138 (9%) 
WHO grade 3/4 weight loss (current) 110 (31%) 93 (24%) 37 (15%) 17 (8%) 39 (10%) 296 (18%) 
TB (any; current) 79 (22%) 80 (20%) 25 (10%) 11 (5%) 46 (12%) 241 (15%) 
WHO grade 3/4 candida (current) 28 (8%) 25 (6%) 17 (7%) 11 (5%) 8 (2%) 89 (6%) 
Fever 100 (28%) 48 (12%) 19 (8%) 20 (9%) 26 (7%) 213 (13%) 
Weight loss (any; patient reported) 253 (71%) 233 (59%) 118 (49%) 82 (38%) 139 (35%) 825 (51%) 
Difficulty walking 154 (43%) 14 (4%) 4 (2%) 8 (4%) 5 (1%) 185 (12%) 
Rash 57 (16%) 63 (16%) 62 (26%) 49 (22%) 70 (18%) 301 (19%) 
Numbness 135 (38%) 76 (19%) 29 (12%) 32 (15%) 40 (10%) 312 (19%) 
Abdominal ache 71 (20%) 40 (10%) 18 (7%) 26 (12%) 17 (4%) 172 (11%) 
Sore mouth/ulcers/candida 57 (16%) 42 (11%) 25 (10%) 18 (8%) 20 (5%) 162 (10%) 
Vomiting 48 (14%) 21 (5%) 4 (2%) 11 (5%) 9 (2%) 93 (6%) 
EQ5D: mobility       
      No problems 79 (22%) 374 (95%) 237 (98%) 202 (93%) 387 (97%) 1279 (80%) 
      Some problems 265 (75%) 20 (5%) 5 (2%) 16 (7%) 11 (3%) 317 (20%) 
      Confined to bed 11 (3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 11 (1%) 
EQ5D: self-care       
      No problems 102 (29%) 378 (96%) 239 (99%) 203 (93%) 389 (98%) 1311 (82%) 
      Some problems 203 (57%) 15 (4%) 3 (1%) 15 (7%) 9 (2%) 245 (15%) 
      Unable 50 (14%) 1 (0%) 0 (0%) 0 (0%) 0 (0%) 51 (3%) 
EQ5D: usual activities       
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 Group 1 Group 2 Group 3 Group 4 Group 5 Total 
 N=355 N=394 N=242 N=218 N=398 1607 
      No problems 25 (7%) 332 (84%) 232 (96%) 185 (85%) 372 (93%) 1146 (71%) 
      Some problems 229 (65%) 60 (15%) 10 (4%) 30 (14%) 26 (7%) 355 (22%) 
      Unable 101 (28%) 2 (1%) 0 (0%) 3 (1%) 0 (0%) 106 (7%) 
EQ5D: pain       
      None 33 (9%) 294 (75%) 204 (84%) 152 (70%) 330 (83%) 1013 (63%) 
      Moderate 290 (82%) 97 (25%) 36 (15%) 63 (29%) 66 (17%) 552 (34%) 
      Extreme 32 (9%) 3 (1%) 2 (1%) 3 (1%) 2 (1%) 42 (3%) 
EQ5D: anxiety       
      Not anxious 134 (38%) 320 (81%) 228 (94%) 163 (75%) 345 (87%) 1190 (74%) 
      Moderately 202 (57%) 69 (18%) 13 (5%) 48 (22%) 50 (13%) 382 (24%) 
      Extremely 19 (5%) 5 (1%) 1 (0%) 7 (3%) 3 (1%) 35 (2%) 












Fat mass (kg) 4.2 (1.7, 7.5) 4.4 (2.9, 7.4) 7.1 (4.0, 11.3) 18.9 (14.4, 24.7) 7.8 (5.4, 12.5) 6.6 (3.7, 12.3) 
Fat free mass (kg) 42.0 (37.8, 47.4) 43.7 (40.0, 48.4) 38.1 (36.0, 40.9) 42.2 (40.2, 44.7) 50.6 (46.5, 55.1) 43.6 (39.2, 49.5) 
MUAC (cm) 22.3 (20.4, 24.4) 22.8 (21.4, 24.1) 22.6 (21.0, 24.0) 28.0 (26.0, 30.1) 25.6 (24.0, 27.7) 24.0 (22.0, 26.1) 
BMI (kg/m2) 17.5 (16.0, 19.7) 18.0 (16.8, 19.3) 18.2 (16.8, 19.7) 23.9 (22.0, 26.3) 20.5 (19.0, 22.8) 19.2 (17.3, 21.4) 
Grip strength (kg) 20.0 (15.0, 26.9) 24.5 (20.8, 30.5) 20.3 (16.8, 23.8) 23.6 (20.3, 27.2) 33.5 (27.8, 38.0) 24.5 (19.4, 31.1) 
CD4 (cells/mm3) 28 (13, 49) 43 (20, 69) 27 (12, 48) 48 (24, 73) 42 (18, 67) 37 (17, 63) 
Haemoglobin (g/dl) 10.1 (8.7, 11.8) 10.3 (9.1, 12.0) 10.7 (9.3, 12.1) 11.4 (10.5, 12.5) 12.8 (11.5, 14.1) 11.2 (9.6, 12.7) 
White blood cells (109/l) 3.5 (2.5, 4.8) 4.4 (3.5, 5.7) 3.0 (2.3, 4.0) 3.2 (2.5, 4.0) 3.4 (2.6, 4.3) 3.5 (2.7, 4.7) 
Platelets (109/l) 247 (177, 329) 307 (223, 413) 266 (184, 370) 240 (186, 325) 225 (167, 291) 255 (184, 345) 
Neutrophils (109/l) 1.71 (1.07, 2.68) 2.49 (1.77, 3.56) 1.42 (0.95, 1.93) 1.54 (1.15, 2.10) 1.59 (1.09, 2.18) 1.74 (1.19, 2.58) 
Albumin (g/l) 32 (26, 37) 32 (28, 36) 37 (32, 41) 38 (34, 42) 39 (35, 42) 35 (30, 40) 
eGFR (ml/min) 87.2 (67.6, 108.5) 95.8 (76.5, 115.4) 105.8 (85.0, 137.5) 107.5 (88.8, 136.9) 95.6 (78.4, 119.5) 97.1 (77.5, 120.9) 
Log10 HIV viral load 5.6 (5.2, 6.0) 5.4 (5.0, 5.8) 5.3 (5.0, 5.7) 5.2 (4.9, 5.6) 5.4 (4.9, 5.7) 5.4 (5.0, 5.8) 
Not included in the cluster analysis       
CD8 (cells/mm3) 408 (257, 643) 528 (352, 801) 446 (303, 764) 523 (355, 700) 499 (335, 719) 479 (310, 724) 
Phosphate (mg/dl) 2.72 (1.25, 3.67) 1.30 (1.01, 2.24) 1.43 (1.14, 3.00) 1.39 (1.01, 3.23) 1.39 (1.04, 3.06) 1.44 (1.06, 3.20) 
Diarrhoea 32 (9%) 22 (6%) 13 (5%) 12 (6%) 20 (5%) 99 (6%) 
Poor appetite/difficulty feeding 212 (60%) 115 (29%) 60 (25%) 59 (27%) 66 (16%) 512 (32%) 
Dehydration 55 (15%) 14 (4%) 3 (1%) 1 (<1%) 2 (1%) 75 (5%) 
Note: factors in bold have p<0.05 in the final multivariable model for mortality. 
